22 Sep 2010
(MENAFN) Dubai-based NewBridge Pharmaceuticals said that it has completed its $12 million Series B financing, bringing the total amount raised to $16 million, Reuters reported.
The Series B financing round was led by Kuwait Life Sciences Company (KLSC), a subsidiary of National Technology Enterprises Company of Kuwait with participation by the previous investor Burrill Life Sciences Capital Fund III, L.P.
NewBridge is a specialty pharmaceutical, biologics, medical devices and diagnostics company serving the emerging markets of Africa, Middle East, Turkey, and Caspian regions.
17 Nov 2024
BBK and Asia Jewellers announce exclusive offers to its customers at Jewellery Arabia 2024
12 Nov 2024
BBK partners with Durrat Al Bahrain to offer exclusive financing for Jawhart Al Marjan
05 Nov 2024
As part of its digital transformation journey, BBK adds Google Wallet to its range of digital wallets
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more